Skip to main content
TipRanks
Go Ultimate75% OFF

Fusion Antibodies Plc (FAB) Share Price & Analysis

10 Followers

FAB Stock Chart & Stats

GBX 4.25GBX 0.00(0.00%)
At close: 4:30 PM GMT
5 p7.5 p10 p12.5 pAug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
GBX 3.56 - GBX 4.50
52-Week Range
GBX 3.50 - GBX 20.00
Previous Close
GBX 4.25
Volume
N/A
Average Volume (3M)
903.25K
Market Cap
GBP 5.32M
Enterprise Value
GBP 13.92M
Total Cash (Recent Filing)
GBP 1.04M
Total Debt (Recent Filing)
GBP 331.00K
Price to Earnings (P/E)
―
Beta
-0.74
Next Earnings
Dec 07, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The strong latest-year revenue rebound indicates renewed customer demand for Fusion Antibodies’ specialized discovery and development services. If sustained, higher activity can improve operating leverage, support broader client engagement, and provide a foundation for scaling the business over the next several quarters.

Gross Margin Improvement

The substantial gross-margin improvement shows that recent revenue is being generated with better direct economics than in prior periods. Maintaining this level would strengthen contribution from projects, improve the potential path toward breakeven, and make future revenue growth more valuable to shareholders.

Contained Leverage

Relatively contained leverage gives the company more financial flexibility than a heavily debt-funded balance sheet would provide. Lower debt pressure can preserve strategic options, reduce the burden of interest and refinancing, and allow management to focus available resources on rebuilding operations and reaching sustainable scale.

Bears Say

Persistent Operating Losses

Large operating and net losses show that the recent revenue recovery has not yet translated into a sustainable earnings model. Continued losses can consume equity, limit internally funded investment, and indicate that the company still needs substantial operating improvement before growth produces durable shareholder returns.

Ongoing Cash Burn

Negative operating and free cash flow means the business is not currently funding its activities from customer receipts and remains reliant on external funding. Even with improved cash burn relative to earlier periods, prolonged deficits can constrain investment, reduce resilience, and increase financing dependence.

Volatile Revenue And Scale Risk

The multi-year revenue volatility makes it difficult to treat the latest rebound as an established growth trajectory. Combined with persistent losses, this suggests the specialized service platform has not yet achieved durable scale, leaving future performance sensitive to the consistency of project demand.

Fusion Antibodies Plc News

FAB FAQ

What was Fusion Antibodies Plc’s price range in the past 12 months?
Fusion Antibodies Plc lowest share price was 3.50 p and its highest was 20.00 p in the past 12 months.
What is Fusion Antibodies Plc’s market cap?
Fusion Antibodies Plc’s market cap is £5.32M.
When is Fusion Antibodies Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Fusion Antibodies Plc’s earnings last quarter?
Fusion Antibodies Plc released its earnings results on Sep 14, 2026. The company reported -0.005 p earnings per share for the quarter.
Is Fusion Antibodies Plc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Fusion Antibodies Plc pay dividends?
Fusion Antibodies Plc does not currently pay dividends.
What is Fusion Antibodies Plc’s EPS estimate?
Fusion Antibodies Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusion Antibodies Plc have?
Fusion Antibodies Plc has 125,156,876 shares outstanding.
What happened to Fusion Antibodies Plc’s price movement after its last earnings report?
Fusion Antibodies Plc reported an EPS of -0.005 p in its last earnings report. Following the earnings report the stock price went down -21.277%.
Which hedge fund is a major shareholder of Fusion Antibodies Plc?
Currently, no hedge funds are holding shares in GB:FAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology